Benefits Outweigh Risks As Europe Okays Sanofi’s Zynquista, Despite Unresolved FDA CRL

 
• By Jo Shorthouse
  
Tandem
The marketing authorization is based on evidence including data from the inTandem clinical trial • Source: Shutterstock

More from New Products

More from Scrip